Neurosense Therapeutics Ltd. (NRSN) has released an update.
NeuroSense Therapeutics Ltd. has successfully completed the 18-month dosing phase of its PARADIGM Phase 2b ALS clinical trial, with top-line clinical results expected in early December 2024. Investors and market watchers will be keenly anticipating these results, which could significantly impact the company’s future prospects and stock performance.
For further insights into NRSN stock, check out TipRanks’ Stock Analysis page.